[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d4.16\u2033 global_colors_info=\u201d{}\u201d][et_pb_row _builder_version=\u201d4.16\u2033 arka plan_size=\u201dinitial\u201d arka plan_pozisyon=\u201dtop_left\u201d arka plan_repeat=\u201dtekrar\u201d global_colors_info=\u201d{}\u201d][et_pb_column type=\u201d4_4\u2033 _builder_version=\u201d4.16\u2033custom_padding=\u201d|||\u201d global_colors_info=\u201d{}\u201dcustom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.20.4\u2033header_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201dcustom_padding =\u201d25px||||false|false\u201d global_colors_info=\u201d{}\u201d]<\/p>\n
Tarihsel olarak a\u011f\u0131z kanserinin ya\u015fa ba\u011fl\u0131 bir malignite oldu\u011fu d\u00fc\u015f\u00fcn\u00fcl\u00fcyordu; ancak ili\u015fkili risk fakt\u00f6rlerinin artan yayg\u0131nl\u0131\u011f\u0131, demografik grubu daha gen\u00e7 ya\u015f gruplar\u0131na do\u011fru geni\u015fletmektedir. Bu endi\u015fe verici de\u011fi\u015fim, proaktif tespit stratejilerinin kritik \u00f6nemini g\u00fcn \u0131\u015f\u0131\u011f\u0131na \u00e7\u0131kar\u0131yor. A\u011f\u0131z kanseri ileri a\u015famalara (III ve IV) kadar tedavi edilmezse be\u015f y\u0131ll\u0131k hayatta kalma oran\u0131 'nin alt\u0131na d\u00fc\u015fer.1<\/sup><\/p>\n Zorluk, semptomlar\u0131n genellikle erken a\u015famalarda g\u00f6zden ka\u00e7\u0131r\u0131lmas\u0131 ger\u00e7e\u011finde yatmaktad\u0131r. Art\u0131k sa\u011flay\u0131c\u0131lar, hastal\u0131k daha tehlikeli bir bi\u00e7ime ilerlemeden \u00f6nce hastalar\u0131 te\u015fhis etmek ve tedavi etmek i\u00e7in zamana kar\u015f\u0131 her zamankinden daha fazla yar\u0131\u015f\u0131yor.<\/p>\n Sa\u011flay\u0131c\u0131lar a\u011f\u0131z kanserini erken a\u015famalarda (I ve II) yakalamay\u0131 ba\u015far\u0131rlarsa, hasta sonu\u00e7lar\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde iyile\u015ftirilebilir. Asl\u0131nda, bu a\u015famalarda ortalama hayatta kalma oran\u0131 'a ula\u015fabilir.1<\/sup> Benzer \u015fekilde, erken te\u015fhis, b\u00fcy\u00fck rekonstr\u00fcktif cerrahi, y\u00fcz protezleri ve i\u015flevi yeniden kazanmak i\u00e7in y\u0131llar s\u00fcren kapsaml\u0131 terapi ihtiyac\u0131n\u0131 ortadan kald\u0131r\u0131r.<\/p>\n Bir\u00e7ok hasta i\u00e7in tan\u0131ya giden yolculuk, erken evre semptomlar\u0131n belirlenmesi ve \u00e7oklu sa\u011flay\u0131c\u0131 de\u011ferlendirme s\u00fcresinin uzat\u0131lmas\u0131 nedeniyle geciktirilmektedir. Kapsam belirleme incelemelerinden biri, hastalar\u0131n oral skuam\u00f6z h\u00fccreli karsinom tan\u0131s\u0131 i\u00e7in alt\u0131 aya kadar beklediklerini ortaya \u00e7\u0131kard\u0131.2<\/sup> Bu tan\u0131sal gecikme, hastan\u0131n durumunu daha da k\u00f6t\u00fcle\u015ftirebilir ve dolay\u0131s\u0131yla tedavi se\u00e7eneklerini, ya\u015fam kalitesini \u00f6nemli \u00f6l\u00e7\u00fcde bozan \u015fekil bozucu operasyonlarla s\u0131n\u0131rland\u0131rabilir. .<\/p>\n A\u011f\u0131z kanseri tan\u0131s\u0131 i\u00e7in ortalama ya\u015f 64 olmas\u0131na ra\u011fmen vakalar\u0131n 'sinden fazlas\u0131 55 ya\u015f\u0131n alt\u0131ndaki hastalarda g\u00f6r\u00fclmektedir.3<\/sup> Bu nedenle, sa\u011flay\u0131c\u0131lar\u0131n semptomlara ve klinik riske kar\u015f\u0131 dikkatli olmalar\u0131 gerekir. Her ya\u015ftan hastada fakt\u00f6rler. A\u011f\u0131z Kanseri Vakf\u0131, hastalar\u0131n 18 ya\u015f\u0131na geldi\u011finde y\u0131ll\u0131k taramalara ba\u015flanmas\u0131n\u0131 \u00f6nermektedir.4<\/sup><\/p>\n Ancak belirli ya\u015fam tarz\u0131 al\u0131\u015fkanl\u0131klar\u0131na sahip hastalar\u0131n standart \u00f6neriden daha \u00f6nce d\u00fczenli taramalara tabi tutulmas\u0131 gerekmektedir. Sigara i\u00e7mek a\u011f\u0131z kanseri riskini on kata kadar art\u0131rd\u0131\u011f\u0131 ve uzun s\u00fcreli dumans\u0131z t\u00fct\u00fcn kullan\u0131m\u0131 riski 50 kat art\u0131rd\u0131\u011f\u0131 i\u00e7in, t\u00fct\u00fcn kullan\u0131m \u00f6yk\u00fcs\u00fc olan hastalar\u0131n taramaya kullan\u0131m\u0131n ba\u015flang\u0131c\u0131nda ba\u015flamas\u0131 gerekir.5<\/sup><\/p>\n A\u011f\u0131z kanserinin \u00f6n\u00fcnde kalmak tutarl\u0131 de\u011ferlendirme ve do\u011fru tarama gerektirir. Vigilant Biosciences\u00ae, te\u015fhis s\u00fcrecinde yeni bir yol olu\u015fturmak i\u00e7in a\u011f\u0131z kanserine ili\u015fkin derin anlay\u0131\u015f\u0131, tespit teknolojisindeki lider uzmanl\u0131kla birle\u015ftiriyor. Vigilant ekibi, sa\u011flay\u0131c\u0131lar\u0131n a\u011f\u0131z kanserini her zamankinden daha erken tan\u0131mlamas\u0131na, te\u015fhis etmesine ve tedavi etmesine yard\u0131mc\u0131 olmak i\u00e7in en ileri \u00e7\u00f6z\u00fcmleri sunmak i\u00e7in aktif olarak \u00e7al\u0131\u015f\u0131yor.<\/p>\n Vigilant Biosciences\u00ae'\u0131n d\u00fcnya \u00e7ap\u0131nda hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftirmek i\u00e7in a\u011f\u0131z kanseri tespitini h\u0131zland\u0131rmaya nas\u0131l yard\u0131mc\u0131 olan sa\u011flay\u0131c\u0131lar oldu\u011fu hakk\u0131nda daha fazla bilgi edinin.<\/a><\/p>\n [\/et_pb_text][et_pb_text _builder_version=\u201d4.20.4\u2033 text_font_size=\u201d14px\u201dheader_2_font_size=\u201d24px\u201dheader_2_line_height=\u201d1.4em\u201dbackground_size=\u201dinitial\u201dbackground_position=\u201dtop_left\u201dbackground_repeat=\u201drepeat\u201d global_colors_info=\u201d{}\u201d ]<\/p>\n Kaynaklar<\/strong><\/p>\n 1. A\u011f\u0131z Kanseri Vakf\u0131. (tarih yok). A\u011f\u0131z Kanseri Vakf\u0131. 15 Mart 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/oralcancerfoundation.org\/?gclid=Cj0KCQjw2cWgBhDYARIsALggUhoUo4AK8qplxhAyEF1r8Pu0iL1nsi4f1WuhDGDsCqfFf8iNco4poz8aAj2FEALw_wcB<\/a> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":" Tarihsel olarak a\u011f\u0131z kanserinin ya\u015fa ba\u011fl\u0131 bir malignite oldu\u011fu d\u00fc\u015f\u00fcn\u00fcl\u00fcyordu; ancak ili\u015fkili risk fakt\u00f6rlerinin artan yayg\u0131nl\u0131\u011f\u0131, demografik grubu daha gen\u00e7 ya\u015f gruplar\u0131na do\u011fru geni\u015fletmektedir. Bu endi\u015fe verici de\u011fi\u015fim, proaktif tespit stratejilerinin kritik \u00f6nemini g\u00fcn \u0131\u015f\u0131\u011f\u0131na \u00e7\u0131kar\u0131yor. A\u011f\u0131z kanseri daha sonraki a\u015famalara (III ve IV) kadar tedavi edilmezse be\u015f y\u0131ll\u0131k hayatta kalma oran\u0131 d\u00fc\u015fer [\u2026]<\/p>","protected":false},"author":3,"featured_media":359,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"Historically, oral cancer was thought to be an age-related malignancy; however, the growing prevalence of associated risk factors expands the demographic to younger age groups. This alarming shift brings to light the critical importance of proactive detection strategies. If oral cancer is left untreated until later stages (III and IV), the five-year survival rate drops to under 50%.1 \r\n\r\nThe challenge lies in the fact that symptoms are typically missed in early stages. Now more than ever, providers are in a race against time to diagnose and treat patients before the disease progresses to a more dangerous form.\r\n\r\nThe need for early detection\r\n\r\nIf providers succeed in catching oral cancer in the earlier stages (I and II), patient outcomes can be significantly improved. In fact, the average survival rate in these stages can reach 90%.1 Likewise, early detection obviates the need for major reconstructive surgery, facial prostheses, and years of extensive therapy to regain function.\r\n\r\nFor many patients, the journey to a diagnosis is delayed by identifying early-stage symptoms and extended multi-provider assessment period. One scoping review found that patients waited up to six months for an oral squamous cell carcinoma diagnosis.2 This diagnostic delay may further escalate a patient\u2019s condition, thereby limiting treatment options to disfiguring operations that significantly impair quality of life.\r\n\r\nPinpointing the right age\r\n\r\nAlthough the average age for an oral cancer diagnosis is 64, more than 20% of cases are found in patients younger than 55 years old.3 As such, providers should be on the lookout for symptoms and clinical risk factors in patients of all ages. The Oral Cancer Foundation recommends annual screenings starting once patients reach 18 years of age.4\r\n\r\nHowever, patients engaging in certain lifestyle habits should undergo regular screenings earlier than the standard recommendation. Patients with a history of tobacco use should start screening at the onset of use, as smoking multiplies the risk of oral cancer up to ten times and long-term smokeless tobacco use increases the risk 50-fold.5\r\n\r\nStaying ahead of oral cancer requires consistent evaluation and accurate screening. Vigilant Biosciences\u00ae pairs a deep understanding of oral cancer with leading expertise in detection technology to forge a new path in the diagnostic process. The Vigilant team is actively working to deliver the most cutting-edge solutions to help providers identify, diagnose, and treat oral cancer earlier than ever.\r\n\r\nLearn more about how Vigilant Biosciences\u00ae is helping providers accelerate oral cancer detection to improve patient outcomes around the world.\r\n____________________________________________________________________________\r\n\r\nSources\r\n\r\nOral Cancer Foundation. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/?gclid=Cj0KCQjw2cWgBhDYARIsALggUhoUo4AK8qplxhAyEF1r8Pu0iL1nsi4f1WuhDGDsCqfFf8iNco4poz8aAj2FEALw_wcB \r\nMauceri, R., Bazzano, M., Coppini, M., Tozzo, P., Panzarella, V., Campisi, G. (2022). Diagnostic delay of oral squamous cell carcinoma and the fear of diagnosis: A scoping review. Frontiers in Psychology 13. \r\nKey Statistics for Oral Cavity and Oropharyngeal Cancers. (2023, January 18). American Cancer Society. https:\/\/www.cancer.org\/cancer\/oral-cavity-and-oropharyngeal-cancer\/about\/key-statistics.html\r\nScreening. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/screening\/ \r\nRisk Factors. (n.d.). Oral Cancer Foundation. Retrieved March 15, 2023, from https:\/\/oralcancerfoundation.org\/cdc\/risk-factors\/","_et_gb_content_width":"","inline_featured_image":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-353","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"yoast_head":"\nErken te\u015fhis ihtiyac\u0131<\/h2>\n
Do\u011fru ya\u015f\u0131 belirlemek<\/h2>\n
2. Mauceri, R., Bazzano, M., Coppini, M., Tozzo, P., Panzarella, V., Campisi, G. (2022). Oral skuam\u00f6z h\u00fccreli karsinomun tan\u0131sal gecikmesi ve tan\u0131 korkusu: Kapsam belirleme incelemesi. Psikolojide S\u0131n\u0131rlar 13.
3. A\u011f\u0131z Bo\u015flu\u011fu ve Orofaringeal Kanserlere \u0130li\u015fkin Temel \u0130statistikler. (2023, 18 Ocak). Amerikan Kanser Toplulu\u011fu. https:\/\/www.cancer.org\/cancer\/oral-cavity-and-oropharyngeal-cancer\/about\/key-statistics.html<\/a>
4. Tarama. (tarih yok). A\u011f\u0131z Kanseri Vakf\u0131. 15 Mart 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/oralcancerfoundation.org\/screening\/<\/a>
5. Risk Fakt\u00f6rleri. (Ve.). A\u011f\u0131z Kanseri Vakf\u0131. 15 Mart 2023'te \u015fu adresten al\u0131nd\u0131: https:\/\/oralcancerfoundation.org\/cdc\/risk-factors\/<\/a><\/p>\n